Central Nervous System–Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma
Open Access
- 20 May 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (7) , 1062-1064
Abstract
Brain metastases (BrM) are among the most common neurologic complications of cancer. In fact, up to 40% of patients with a metastatic malignant tumor will develop BrM during their lifetime.1 Historically, patients with BrM have been excluded from clinical trials due to concerns about poor prognosis and increased risk of neurologic toxic effects.2 This has resulted in a scarcity of evidence for the efficacy of systemic therapies in the central nervous system (CNS). Our objective was to determine the proportion of phase 3 clinical trials investigating a systemic therapy intervention for patients with metastatic breast cancer, lung cancer, and melanoma that included patients with BrM and/or evaluated CNS-specific end points.Keywords
This publication has 6 references indexed in Scilit:
- Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility QuotientJournal of Clinical Oncology, 2020
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementJournal of Clinical Oncology, 2017
- Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanomaNeuro-Oncology, 2016
- Response assessment criteria for brain metastases: proposal from the RANO groupThe Lancet Oncology, 2015
- Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupThe Lancet Oncology, 2013
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999